Keryx Biopharmaceuticals, Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2018. For the quarter, the company reported total revenue of $25,749,000 as compared to $15,144,000 for the same period last year. Operating Loss was $20,151,000 as compared to $23,850,000 for the same period last year. Loss Before Income Taxes was $21,518,000 as compared to $86,477,000 for the same period last year. Net Loss was $21,518,000 as compared to $86,497,000 for the same period last year. Basic and diluted net loss per common share was $0.18 as compared to $0.77 for the same period last year. For the six months, the company reported total revenue of $47,500,000 as compared to $26,964,000 for the same period last year. Operating Loss was $42,903,000 as compared to $46,960,000 for the same period last year. Loss Before Income Taxes was $44,048,000 as compared to $109,473,000 for the same period last year. Net Loss was $43,414,000 as compared to $109,513,000 for the same period last year. Basic and diluted net loss per common share was $0.36 as compared to $1.00 for the same period last year.